The Safety and Efficacy of an Investigational Drug in Delaying the Progression of Alzheimer's Disease - Full Text View

Sponsor:	Merck
Information provided by:	National Institute on Aging (NIA)
ClinicalTrials.gov Identifier:	NCT00006187

Purpose

This is a 15-month study with two phases. During the first 12-month phase of this study, patients will be randomly assigned to receive either active study drug or placebo (approximately half of all patients will be on active study drug, the other half on placebo). The second phase is a 3-month randomized withdrawal period. For this phase approximately 10% of the patients will remain on the active drug.

Condition	Intervention	Phase
Alzheimer Disease	Drug: Investigational drug	Phase III

Study Type:	Interventional
Study Design:	Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study

Resource links provided by NLM:

Genetics Home Reference related topics: Alzheimer disease

MedlinePlus related topics: Alzheimer's Disease

U.S. FDA Resources

Further study details as provided by National Institute on Aging (NIA):

Estimated Study Completion Date:

March 2001

Detailed Description:

This is a placebo-controlled, parallel-groups, 12 month, double-blind study, followed by a 3-month, double-blind, randomized withdrawal period to evaluate the efficacy and safety of an investigational drug (currently approved for other indications) to slow the progression of symptoms of AD. Patients with probable AD according to NINCDS-ADRDA criteria who have a Mini Mental State Examination (MMSE) score between 13 and 26 inclusive will be eligible for participation in the study.

Patients on stable doses of marketed cholinesterase inhibitors approved for the treatment of AD (except for tacrine) for at least 3 months are eligible for study entry. Use of NSAIDs (except aspirin 81 mg per day) is not allowed during the study.

Eligibility

Ages Eligible for Study:	50 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Patient is male or female and at least 50 years of age or older
Female patients must be postmenopausal or surgically sterilized
Clinical diagnosis of AD
Patient must be in good health except for AD diagnosis
Patient must have informant/caregiver who can monitor and assist patient during the study

Exclusion Criteria:

Patient is living in a nursing home or skilled nursing facility
Women will be ineligible if not postmenopausal or surgically sterilized
Site physician or Sponsor may exclude patients with serious medical problems such as cancer, cardiovascular disease, major neurological or psychiatric illness, thyroid disease, or major head trauma

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00006187

Show 34 Study Locations

Sponsors and Collaborators

Merck

Investigators

Principal Investigator:

Klaus Beck, MD, PhD

Merck

More Information

No publications provided

Study ID Numbers:	IA0025
Study First Received:	August 25, 2000
Last Updated:	June 23, 2005
ClinicalTrials.gov Identifier:	NCT00006187 History of Changes
Health Authority:	Unspecified

Keywords provided by National Institute on Aging (NIA):

Investigational Drug

Additional relevant MeSH terms:

Delirium, Dementia, Amnestic, Cognitive Disorders
Mental Disorders
Nervous System Diseases
Alzheimer Disease
Central Nervous System Diseases

Neurodegenerative Diseases
Tauopathies
Brain Diseases
Dementia

ClinicalTrials.gov processed this record on November 09, 2009